Xofyl 200 mg is a bronchodilator medication containing Doxophylline, a novel xanthine derivative. It differs from Theophylline by incorporating a dioxolane group at the N-7 position, which enhances its selectivity and safety profile. Doxophylline primarily inhibits phosphodiesterase 4 (PDE4), leading to the relaxation of bronchial smooth muscles and improved airflow. Additionally, it has reduced affinity for adenosine A1 and A2 receptors, contributing to fewer side effects. The drug also inhibits platelet-activating factor (PAF) and the generation of leukotrienes, which are involved in inflammatory responses.